Antisense Therapy for Infectious Diseases
Infectious diseases, particularly Tuberculosis (TB) caused by <i>Mycobacterium tuberculosis</i>, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectio...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/16/2119 |
| _version_ | 1797585201400905728 |
|---|---|
| author | Lwanda Abonga Buthelezi Shandre Pillay Noxolo Nokukhanya Ntuli Lorna Gcanga Reto Guler |
| author_facet | Lwanda Abonga Buthelezi Shandre Pillay Noxolo Nokukhanya Ntuli Lorna Gcanga Reto Guler |
| author_sort | Lwanda Abonga Buthelezi |
| collection | DOAJ |
| description | Infectious diseases, particularly Tuberculosis (TB) caused by <i>Mycobacterium tuberculosis</i>, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases. |
| first_indexed | 2024-03-11T00:02:41Z |
| format | Article |
| id | doaj.art-b8987df7b2974032b48b54e63c775ce5 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T00:02:41Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-b8987df7b2974032b48b54e63c775ce52023-11-19T00:37:50ZengMDPI AGCells2073-44092023-08-011216211910.3390/cells12162119Antisense Therapy for Infectious DiseasesLwanda Abonga Buthelezi0Shandre Pillay1Noxolo Nokukhanya Ntuli2Lorna Gcanga3Reto Guler4International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South AfricaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South AfricaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South AfricaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South AfricaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South AfricaInfectious diseases, particularly Tuberculosis (TB) caused by <i>Mycobacterium tuberculosis</i>, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.https://www.mdpi.com/2073-4409/12/16/2119antisense oligonucleotideantisense therapymRNAinfectious disease |
| spellingShingle | Lwanda Abonga Buthelezi Shandre Pillay Noxolo Nokukhanya Ntuli Lorna Gcanga Reto Guler Antisense Therapy for Infectious Diseases Cells antisense oligonucleotide antisense therapy mRNA infectious disease |
| title | Antisense Therapy for Infectious Diseases |
| title_full | Antisense Therapy for Infectious Diseases |
| title_fullStr | Antisense Therapy for Infectious Diseases |
| title_full_unstemmed | Antisense Therapy for Infectious Diseases |
| title_short | Antisense Therapy for Infectious Diseases |
| title_sort | antisense therapy for infectious diseases |
| topic | antisense oligonucleotide antisense therapy mRNA infectious disease |
| url | https://www.mdpi.com/2073-4409/12/16/2119 |
| work_keys_str_mv | AT lwandaabongabuthelezi antisensetherapyforinfectiousdiseases AT shandrepillay antisensetherapyforinfectiousdiseases AT noxolonokukhanyantuli antisensetherapyforinfectiousdiseases AT lornagcanga antisensetherapyforinfectiousdiseases AT retoguler antisensetherapyforinfectiousdiseases |